Sienna Biopharmaceuticals Inc
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical … Read more
Sienna Biopharmaceuticals Inc (SNNAQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2019: -0.772x
Based on the latest financial reports, Sienna Biopharmaceuticals Inc (SNNAQ) has a cash flow conversion efficiency ratio of -0.772x as of September 2019.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.84 Million) by net assets ($23.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sienna Biopharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2018)
This chart illustrates how Sienna Biopharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sienna Biopharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sienna Biopharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
International Company For Fertilizers & Chemicals
EGX:ICFC
|
N/A |
|
3P Land Holdings Limited
NSE:3PLAND
|
0.000x |
|
Hotland Yantian Port Warehouse Logistics
SHE:180301
|
N/A |
|
Pebble Beach Systems Group PLC
LSE:PEB
|
-7.815x |
|
Ba Ria Thermal Power JSC
VN:BTP
|
-0.010x |
|
VELOGIC HOLDING COMPANY LIMITED
SEM:VELG
|
N/A |
|
Ruzy Madencilik ve Enerji Yatirimlari Sanayi ve Ticaret A.S.
IS:RUZYE
|
N/A |
|
Fluoropharma Medical
PINK:FPMI
|
0.011x |
Annual Cash Flow Conversion Efficiency for Sienna Biopharmaceuticals Inc (2015–2018)
The table below shows the annual cash flow conversion efficiency of Sienna Biopharmaceuticals Inc from 2015 to 2018.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2018-12-31 | $26.58 Million | $-61.69 Million | -2.321x | -415.21% |
| 2017-12-31 | $91.20 Million | $-41.08 Million | -0.450x | +43.65% |
| 2016-12-31 | $22.12 Million | $-17.68 Million | -0.799x | +67.55% |
| 2015-12-31 | $4.05 Million | $-9.98 Million | -2.463x | -- |